# Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia

> **NCT04609865** · PHASE3 · TERMINATED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 14 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome (ARDS)
- COVID-19
- Corona Virus Infection

## Interventions

- **DRUG:** Lidocaine 2%
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT04609865
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-04
- **Primary completion:** 2022-03-17
- **Final completion:** 2022-03-17
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** departure of the principal investigator and inclusion difficulties
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609865, "Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04609865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*